Chymase-dependent angiotensin II forming system in humans

American Journal of Hypertension

Volumn 9, Issue 3, 1996, Pages 277-284

  Urata, Hidenori ^a   Nishimura, Hikaru ^a   Ganten, Detlev ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Angiotensin I converting enzyme,; Angiotensin II; Blood vessel; Chymase; Heart

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN;

CARDIOVASCULAR SYSTEM; DRUG TISSUE LEVEL; HEART DISEASE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029940121     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(95)00349-5     Document Type: Article

References (63)

1. Lindpaintner K, Ganten D: The cardiac reninangiotensin system: an appraisal of present experimental and clinical evidence. Circ Res 1991;68:905-921.
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984;144:1947-1953.
3. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Mento PF, Wiles BM: Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987;9(suppl III):III-42-III-48.
5. Rousseau MF, Konstam MA, Benedict CR, et al: Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-493.
6. Serruys PW: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86:100-110.
7. Faxon DP, on behalf of the MARCATOR Investigators: Angiotensin converting enzyme inhibition and restenosis: the final results of the MARCATOR trial (abst), Circulation 1993;86(suppl I):I53.
8. Desmet W, Vrolix M, De Scheerder I, et al: Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation 1994;89:385-392.
9. Powell JS, Clozel JP, Müller RKM, et al: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245: 186-188.
10. Clozel JP, Hess P, Michael C, et al: Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension 1991;18(suppl II):II-55-II-59.
11. Okunishi H, Oka Y, Shiota N, et al: Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 1993; 62:207-210.
12. Cornish KG, Joyner WL, Gilmore JP: Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res 1979;44:540-544.
13. Trachte GJ, Lefer AM: Inotropic and vasoactive effects of the naturally occurring angiotensins in isolated cat cardiac muscle and coronary arteries. Res Commun Chem Pathol Pharmacol 1979;25:419-427.
14. Cornish KG, Joyner WL, Gilmore JP: Evidence for the conversion of angiotensin I to angiotensin II by the coronary microcirculation. Blood Vessels 1979;16:241-246.
15. Okunishi H, Miyazaki M, Toda N: Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984;2:277-284.
16. Okunishi H, Miyazaki M, Okamura T, Toda N: Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987;149:1186-1192.
17. Nussberger J, Brunner DB, Waeber B, Brunner HR: Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986;8:476-482.
18. Ideishi M, Sasaguri M, Ikeda M, Arakawa K: Substrate-dependent angiotensin II formation in the peripheral circulation. Life Sci 1990;46:335-341.
19. Gondo M, Maruta H, Arakawa K: Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jpn Heart J 1989;30:219-229.
20. Noda K, Sasaguri M, Ideishi M, et al: Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 1993; 27:334-340.
21. Hirakata H, Fouad-Tarazi FM, Bumpus FM, et al: Angiotensins and the failing heart: enhanced positive inotropic response to angiotensin I in isolated cardiomyopathic hamster heart in the presence of captopril. Circ Res 1990;66:891-899.
22. Lindberg BF, Nilsson LG, Hedlund H, et al: Angiotensin I is converted to angiotensin II by a serine protease in human detrusor smooth muscle. Am J Physiol 1994; 266:R1861-R1867.
23. 12)-angiotensin I. Hypertension 1994;23:857-860.
24. Hoit BD, Shao Y, Kinoshita A, et al: Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest 1995;95: 1519-1527.
25. Urata H, Healy B, Stewart RW, et al: Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-890.
26. Urata H, Kinoshita A, Misono KS, et al: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265:22348-22357.
27. Le Trong H, Neurath H, Woodbury RG: Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci USA 1987;84:364-367.
28. Urata H, Ganten D: Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase. Eur Heart J 1993;14(suppl I):177-182.
29. Urata H, Hoffmann S, Ganten D: Tissue angiotensin II system in the human heart. Eur Heart J 1994;15(suppl D):68-78.
30. Urata H, Boehm KD, Philip A, et al: Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91: 1269-1281.
31. Vago T, Bevilacqua M, Conci F, et al: Angiotensin converting enzyme binding sites in human heart and lung: comparison with rat tissues. Br J Pharmacol 1992;107: 821-825.
32. Schunkert H, Jackson B, Tang SS, et al: Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993;87:1328-1339.
33. Hirsch AT, Talsness CE, Schunkert H, et al: Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69: 475-482.
34. Lindpaintner K, Jin MW, Niedermaier N, et al: Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res 1990;67:564-573.
35. Linz W, Scholkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy. Clin Exp Hypertens [A] 1989;A11:1325-1350.
36. Pfeffer JM, Pfeffer MA, Braunwald E: Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
37. Nishimura H, Oka T, Ueyama M, et al: Converting enzyme inhibition improves congestion and survival in hypertensive rats with high-output heart failure. J Cardiovasc Pharmacol 1994;23:149-154.
38. Chen S, Chang M, Chiang BM, et al: Electromechanical effects of angiotensin in human atrial tissues. J Moll Cell Cardiol 1991;23:483-493.
39. Husain A, Kinoshita A, Sung SS, et al: Human heart chymase, in Lindpaintner K, Ganten D (eds): The Cardiac Renin-Angiotensin System. Futura Publishing, New York, 1994, pp 309-331.
40. Holubarsch C, Hasenfuss G, Schmidt-Schweda S, et al: Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium: an in vitro study under physiological experimental conditions. Circulation 1993;88:1228-1237.
41. Okunishi H, Kawamoto T, Kurobe Y, et al: Pathogenetic role of vascular angiotensin converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 1991;18:649-659.
42. Shiota N, Miyazaki M, Okunishi H: Increase of angiotensin converting enzyme gene expression in the hypertensive aorta. Hypertension 1992;20:168-174.
43. Nishimura H, Kubota J, Okabe M, et al: Effects of lisinopril upon cardiac hypertrophy, central and peripheral hemodynamics and neurohumoral factors in spontaneously hypertensive rats. J Hypertens 1992;10:431-436.
44. Austin GE, Ratliff NB, Hollman J, et al: Intimai proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-375.
45. Daemaen MJAP, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-456.
46. Sharifi BG, LaFleur DW, Pirola CJ, et al: Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. J Biol Chem 1992;267:23910-23915.
47. 1 receptors in neointima of rat aorta. J Clin Invest 1992;90:1707-1712.
48. Rakugi H, Kim DK, Krieger JE, et al: Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest 1994;93:339-346.
49. Lam JYT, Lacoste L, Bourass MG: Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries. Circulation 1992;85:1542-1547.
50. Hanson SR, Powell JS, Dodson T, et al: Effects of angiotensin converting enzyme inhibition with cilazapril on intimai hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 1991;18(suppl II):II-70-II-76.
51. Shiota N, Okunishi H, Fukamizu A, et al: Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett 1993;323:239-242.
52. Okunishi H, Shiota N, Fukamizu A, et al: Angiotensin II antagonist, not ACE inhibitor, prevents neointimal formation on injured canine arteries (abst). J Hypertens 1994;12(suppl 3):S132.
53. Shiota N, Takai S, Okunishi H, et al: Angiotensin II generating chymase from hamster: molecular cloning (abst). Jpn J Pharmacol 1995;(suppl I):98.
54. Swedberg K, Held P, Kjekshus J, et al on behalf of the CONSENSUS II Study Group: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992;327: 678-684.
55. Popma JJ, Califf RM, Topol EJ: Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84: 1426-1436.
56. Stoll M, Steckelings UM, Paul M, et al: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-657.
57. Miura S, Ideishi M, Sakai T, et al: Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994;12:1177-1181.
58. Urabe Y, Ideishi M, Sasaguri M, et al: Beneficial effects of a serine protease inhibitor in peripheral vascular disease. Am J Cardiol 1993;72:218-222.
59. Cornish KG, Gilmore JP: Angiotensin I conversion by the microcirculation of the nonhuman primate. Blood Vessels 1981;18:128-133.
60. Juul B, Aalkjær C, Mulvany MJ: Contractile effects of tetradecapeptide renin substrate on rat femoral resistance vessels. J Hypertens 1987;5(suppl 2):S7-S10.
61. Okamura T, Okunishi H, Ayajiki K, Toda N: Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol 1990;15: 353-359.
62. Juillerat L, Nussberger J, Ménard J, et al: Determinants of angiotensin II generation during conveting enzyme inhibition. Hypertension 1990;16:564-572.
63. Aldigier JC, Huang H, Dalmay F, et al: Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993;21:289-295.